期刊文献+

血液稀释净化生物平衡疗法治疗非酒精性脂肪肝的研究 被引量:5

Study of equilibrium therapy of decontamination living creature of blood dilution on non-alcoholic fatty liver disease
下载PDF
导出
摘要 目的探讨血液稀释净化生物平衡疗法(ETBD)治疗非酒精性脂肪肝(NAFLD)的效果、安全性、实用性。方法将158例B超诊断的NAFLD随机分为治疗组79例,给予常规药物加ETBD;对照组79例,给予单纯常规药物,于治疗前及治疗后1个月2组分别做血尿常规、血脂、血糖、血液流变学、转氨酶、心电图、肝脏B超等检查。结果治疗组转氨酶、血脂、血液流变学指标均有不同程度的好转(P<0.05或0.01),对照组无明显变化(P>0.05),且未发现明显的不良反应。结论血液黏度增高在NAFLD的发病和病情进展中有某种促进作用;ETBD改善了肝窦周围由于脂肪堆积而引起的氧供和微循环障碍,打断了NAFLD的恶性病理循环。ETBD治疗NAFLD安全、有效。 Objective It is to discuss the effect, safety and practicality of equilibrium therapy of decontamination living creature of blood dilution (ETBD) on non-alcoholic fatty liver disease (NAFLD). Methods 158 cases of NAFLD who were diagnosed with B-mode ultrasonography were randomly divided into two groups. 79 cases were in treatment group and treated with routine medicine and ETBD. Other 79 cases were in control group and treated with routine medicine only. Blood routine, urine routine, blood fat, blood sugar, hemorheology, aminopherase, electrocardiogram and liver B-mode ultrasonography in the two groups were detected before treatment and one month after treatment. Results Aminopherase, blood fat and hemorheology in treatment group had different degree improvement (P 〈 0.05 or 0.01 ). Control group had no obvious changes (P 〉0.05). No obvious untoward reaction was found. Conclusion Blood viscosity increased has some auxoaction in NAFLD onset and pathogenetic condition progression. ETBD improves the disorder of oxygen supply and microcircnlation which is induced by fat cumulate around sinus hepaticus and interrupts the telephic pathological cycle. NAFLD treated with ETBD is safe and effective.
出处 《现代中西医结合杂志》 CAS 2007年第11期1449-1451,共3页 Modern Journal of Integrated Traditional Chinese and Western Medicine
关键词 非酒精性脂肪肝 血液稀释净化生物平衡疗法 血脂 转氨酶 血液流变学 non-alcoholic fatty liver disease equilibrium therapy of decontamination living creature of blood dilution blood fat aminopherase hemorheology
  • 相关文献

参考文献9

二级参考文献17

  • 1[1]Bacon BR, Farahavash M J, Janneucy CG, et al. Nonalcoholic steatohepatitis: an expand clinical entity[J]. Gastroenterology, 1994,107(4):1103- 1109. 被引量:1
  • 2[3]Saverymuttu S H, Joseph AE, Maxwell JD. Ultrosound scanning in the detection of hepatic fibrosis and steatosis[J]. Br Med J, 1986,292:13 -15. 被引量:1
  • 3[4]Vincent F, Mauro, Joanne L. MacDondid, Simvastatin: A review of its pharmacology and clinical use. DICP[J]. Ann Phatmcother, 1991,2.5:1257- 1264. 被引量:1
  • 4Farrell G C. Non-alcoholic steatohepatitis: What is it, and why is it important in the Asia-pacific region? J Gastrenterol Hepatol, 2003,18: 124-138. 被引量:1
  • 5Wanless IR, Lentz JS. Fatty liver hepatitis(steatohepatitis)and obese: an autopsy study with analysis of risk factors. Hepatology, 1990,12: 1106-1110. 被引量:1
  • 6Silverman JF, O'Brien KF, Long S, et al. Liber pathology in morbidly obese patients with and without diabetes. Am J Gastroenterol, 1990,85: 1349-1355. 被引量:1
  • 7Teli MR, James OFR, Burt JA, et al. The nature history of nonalcoholic fatty liver disease:a follow up study. Hepatology, 1995,22: 594-598. 被引量:1
  • 8Matteoni CA, Younossi ZM, Gramlich T, et al. Nonalcoholic fatty liver disease, a spectrum of clinical and pathological severity. Gastrenterology, 1999,116: 1413-1419. 被引量:1
  • 9Tominaga K, Kurata JH, Chen YK, et al. Prevalence of fatty liver in Japanese children and relationship to obesity. Dig Dis Sci, 1995,4: 2002-2009. 被引量:1
  • 10Younossi ZM, Diehl AM, Ong JP, Nonalcoholic fatty disease: an agenda for clinical research. Hepatology, 2002,35: 746-752. 被引量:1

共引文献458

同被引文献34

引证文献5

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部